The risk for sudden cardiac death (SCD) in adolescents and young adults with hypertrophic cardiomyopathy (HCM) is "an order of magnitude lower" than most recent estimates would indicate, a report ...

A small panel of circulating biomarkers may reliably distinguish hypertrophic cardiomyopathy (HCM) from similar conditions that cause left ventricular hypertrophy (LVH), researchers found. From ...

The AI model MAARS showed good results flagging arrhythmic risk in hypertrophic cardiomyopathy. MAARS takes inputs from electronic medical records, cardiac MRI scans with late gadolinium enhancement, ...

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular condition. It is the leading cause of sudden cardiac death in young people and children, with an annual mortality rate of 1% ...

Medically reviewed by Sameena Zahoor, MD Key Takeaways People with hypertrophic cardiomyopathy (HCM) have a higher risk of becoming severely ill from COVID-19.COVID-19 can cause heart damage and lead ...

Future Cardiol. 2013;9(5):697-709. Geometry Asymmetric hypertrophy out of proportion to hypertension Concentric remodeling or hypertrophy Symmetric LV hypertrophy that is proportional to exercise ...

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...

Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III EXPLORER-HCM trial has demonstrated that the novel cardiac myosin inhibitor ...

Hypertrophic cardiomyopathy (HCM) is the leading cause of sudden cardiac death (SCD) in young athletes, according to the ...

SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the launch of EARTH-HCM (Epidemiology, Awareness, Real-world Treatment and ...